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doi:10.1016/j.jtcvs.2006.05.012bjective: The impact of induction chemotherapy on postoperative complications
fter pneumonectomy remains unclear. The aim of the study was to test the
ypothesis that chemotherapy may increase the risk of postoperative respiratory
omplications.
ethods: Data from 202 consecutive standard pneumonectomies performed for lung
ancer were collected and analyzed. Postoperative and 90-day mortality, overall
orbidity, and respiratory complication rates were evaluated in patients who had no
nduction treatment (group A, n  103) as well as in those who received it (n  99,
roup B). Preoperative chemotherapy was inserted as a variable together with 12
ther variables (age, sex, smoking status, body mass index, previous cardiac event,
merican Society of Anesthesiologists score, preoperative forced expiratory vol-
me in 1 second [percent], diffusion capacity for carbon monoxide adjusted for
lveolar volume [percent], side of pneumonectomy, perfusion of the removed lung,
perating time, and blood transfusion) into univariate and multivariate logistic
egression.
esults. No difference in terms of mortality was recorded between group A (4.9%)
nd group B (3%, P .05). Respiratory complications were more frequent in group
than in group A (19 cases, 19.2%, vs 7 cases, 6.8%, P .008). Univariate logistic
egression has demonstrated that pulmonary complications were more frequent in
atients over the age of 70 than in those aged 70 or less (25.7% vs 10.2, P  .02),
n those with a lower diffusion capacity adjusted for alveolar volume (18.3% vs
.95%, P  .06), and in patients who received preoperative chemotherapy (19.2%
s 6.8, P  .008). Logistic regression confirmed the role of age (odds ratio  6.3),
reoperative chemotherapy (odds ratio  4.4), and diffusion capacity adjusted for
lveolar volume (odds ratio  0.33) as risk factors of respiratory complications.
onclusions. Standard pneumonectomy is a safe procedure even after induction
hemotherapy, with a mortality rate in the order of 5%, but this increases in patients
ver the age of 70 years. In the case of induction chemotherapy, the risk of
espiratory complications is significantly increased, apparently not affecting the
verall mortality rate.
 
he first successful pneumonectomy for lung cancer was performed on April
5, 1933, by Evarts Graham for a T2 N1 squamous cell carcinoma.1,2 A few
years later, Overholt3 reported a mortality rate of 33.3% after pneumonec-
omy for malignant disease.
Since then, improvements in surgical techniques as well as in thoracic anesthesia
ave dramatically improved postoperative mortality, and in 1983 the Lung Cancer
tudy Group reported an overall mortality rate of 6.2% after pneumonectomy as
ompared with a mortality of 2.9% after lobectomy.4
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5
G
TSThe occurrence of respiratory complications is consid-
red to be the most dangerous event after pneumonectomy,
ecause “one-lung” patients are at high risk of respiratory
ailure when such complications occur.
Whether or not chemotherapy acts as an additional risk
actor in respiratory complications is still controversial.5,6
rom a theoretical point of view, the impairment of the
lveolocapillary membrane, which is expected after chemo-
herapy,7 could be synergic with other risk factors such as
ge or fluid overload in causing lung damage.
The general aim of this study was to review our mortality
nd morbidity rates after standard pneumonectomy, verify-
ng the impact of preoperative chemotherapy on the inci-
ence of respiratory complications.
atients and Methods
im
he study investigates the validity of the hypothesis that stan-
ard pneumonectomy represents a higher risk of postoperative
ulmonary complications when performed after induction chemo-
herapy.
opulation
he database of the Thoracic Surgery Department of the European
nstitute of Oncology was reviewed to identify all patients who
nderwent standard pneumonectomy for lung cancer between
anuary 1998 and August 2005.
Standard pneumonectomy was defined as the intrapericardial
r extrapericardial removal of the entire lung, associated with
adical mediastinal lymph node dissection without any resection
f mediastinal, chest wall, or diaphragmatic structure. Patients
ho received preoperative radiotherapy were excluded from the
tudy.
Preoperative respiratory function was assessed routinely by
lood gas analysis, spirometry, and lung perfusion scan. Intraop-
rative management was focused on maximally reducing risk of
amage to the controlateral lung; fluid administration was in the
rder of 5 to 7 mL/kg/h crystalloid infusion, not exceeding a total
mount of 1500 mL in all cases. Ventilation was managed by a
rotective-ventilation strategy (a tidal volume  6 mL/kg, driving
ressure  20 cm H2O above the positive end-expiratory pressure,
ermissive hypercapnia, and the preferential use of pressure-limited
entilatory modes).8 Postoperatively, patients had 2 assisted ses-
ions of chest physiotherapy daily starting on the first postopera-
ive day and were asked to repeat the physiotherapy program 6
Abbreviations and Acronyms
ARDS  acute respiratory distress syndrome
Dlco  diffusion capacity for carbon monoxide
Dlco/VA diffusion capacity for carbon monoxide
adjusted for alveolar volume
OR  odds ratioimes during the day until discharge. Amoxicillin–clavulanic acid 
20 The Journal of Thoracic and Cardiovascular Surgery ● Septeas administered for the first 5 postoperative days in nonallergic
atients.
ostoperative Complications
ostoperative death was defined as any death occurring during the
ostoperative hospital stay or during the first month after sugery;
0-day death was defined as any death occurring within 3 months
rom the day of pneumonectomy.
Respiratory complications were classified as follows: (1) acute
espiratory failure, defined as postoperative ventilator dependence
or more than 12 hours or reintubation for controlled ventilation or
eed of non-invasive ventilation; (2) acute respiratory distress
yndrome (ARDS), defined as respiratory failure with acute onset,
rterial oxygen tension/fraction of inspired oxygen less than 200
m Hg, infiltrates seen on chest x-ray film, and pulmonary wedge
ressure less than 18 mm Hg; (3) acute lung injury, defined with
he same criteria as ARDS but with arterial oxygen tension/
raction of inspired oxygen less than 300 mm Hg; (4) pneumonia,
efined by the presence of at least 3 of the following criteria:
ersistent lung infiltrate on chest x-ray film, fever greater than 38°C,
hite cell blood count greater than 10,000/mm3 or less than 3000/
m3, purulent secretions, and documented presence of microor-
anisms on sputum or bronchoaspirate; (5) sputum retention, de-
ned as lobar or whole-lung atelectasis requiring bronchoscopy;
6) pulmonary embolism, documented by lung ventilation/perfu-
ion scintigraphy or angioscan; (7) pulmonary edema, defined as a
ransient respiratory failure reversed by administration of diuretics;
nd (8) chronic respiratory failure, defined as the need for contin-
ous oxygen therapy for more than 1 month after discharge.
Other considered complications were cardiac (cardiac rhythm
roblems, angina, myocardial infarction, cardiogenic shock), sur-
ical (hemothorax, bronchial fistula, empyema, chylothorax, car-
iac dislocation), and others.
Overall mortality and morbidity and respiratory complication
ates were analyzed for the entire population: patients who had
eceived no induction chemotherapy (group A) and patients who
ad received induction therapy (group B).
tatistical Analysis
roup A and group B were compared for all relevant variables,
ncluding demographics and all possible risk factors for postoper-
tive complications, using frequency tables for categorical vari-
bles and summary statistics (n, mean, median, standard deviation,
inimum, and maximum) for continuous variables. The 2 or
isher exact test was applied where appropriate.
Pulmonary complications and postoperative complications
ther than pulmonary were considered as outcome variables in a
ogistic regression model, using the following covariates (risk
actors): age, sex, smoking status, body mass index, previous
ardiac event, American Society of Anesthesiologists score, pre-
perative forced expiratory volume in 1 second (percent), diffusion
apacity for carbon monoxide adjusted for alveolar volume (Dlco/
A%), induction chemotherapy, side of pneumonectomy, perfu-
ion of the removed lung, operating time, and blood transfusion.
dds ratio (OR) and the corresponding 95% confidence intervals
ere reported for covariates that were considered clinically rele-
ant or statistically significant at the .05 significance level (Wald
2 test) and then included in the final multivariate model.
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G
TSesults
opulation
uring the considered period, 202 patients underwent stan-
ard pneumonectomy (146 men, median age 63 years).
here were 96 right and 106 left pneumonectomies, of
hich 63 were performed by opening the pericardium.
ean preoperative forced expiratory volume in 1 second
as 2.3  0.68 (median of percent of predicted value 80%)
nd Dlco/VA 1.2  0.38 (87.5%). Preoperative median
erfusion of the lung to be removed was 37%, as docu-
ented by lung perfusion scan.
One hundred three patients did not receive any chemo-
herapy before surgery (group A, 51%). Ninety-nine pa-
ients (group B, 49%) received preoperative platin-based
hemotherapy; 80 of them completed the planned treatment,
onsisting of 3 or 4 courses of cisplatin and gemcitabine
cisplatinum 80 mg/m2 on days 1 and 21; gemcitabine 1250
g/m2 on days 1, 8, and 21). Eleven patients received only
or 2 courses of cisplatin and gemcitabine, stopping treat-
ent for toxicity. No significant difference between the 2
roups was evident in terms of age, sex, smoking status,
ody mass index and American Society of Anesthesiolo-
ists score. Group B had a higher incidence of advanced-
tage disease than did group A (P  0.03), mainly because
f the higher proportion of patients with stage III disease.
our patients had stage IV disease, 2 in each group. In 3
ases stage IV disease was due to the presence of a single
etastatic nodule in another lobe. The fourth patient with
tage IV disease had isolated cerebral metastasis treated by
urgery and radiotherapy 18 months before pneumonec-
omy. The mean preoperative Dlco/VA was 91.6% in group
 and 83.4% in group B (P  .006, Table 1).
verall Mortality and Morbidity
ight patients died in the postoperative period and 1 patient
ied 6 weeks after discharge (overall mortality 4.5%).
auses of postoperative deaths were ARDS in 3 patients,
ABLE 1. Clinical characteristics of the population
Overall (n  20
en 146
ge (y) 62 9
ardiac history 58
EV1 (%) 79.9  18.8
lco (%) 68.5 16.7
lco/VA (%) 87.5 19.5
tage III-IV (stage IV within parentheses) 93
ight pneumonectomy 96
ntrapericardial 63
perating time, min (mean) 144.1 38.8
values 0.05 are given in bold. FEV1, Forced expiratory volume in 1 sec
or carbon monoxide adjusted for alveolar volume.neumonia in 2, and acute respiratory failure in 2 patients. H
The Journal of Thoracicne patient died of gastric hemorrhage after 1 month in the
ntensive care unit. The late death was due to bronchial
stula.
No difference in terms of mortality was recorded be-
ween group A (4.9%) and group B (3%, P  .05).
Postoperative complications occurred in 88 patients
43.4%) (Table 2). Sixty-two patients had nonrespiratory com-
lications (atrial fibrillation in 35 patients, bronchial fistula
n 11 patients, rethoracotomy for hemothorax in 23 patients,
nd other complications in 18 patients). The incidence of
ethoracotomy because of bleeding was higher in the che-
otherapy group (15.1% vs 7.8%, P  .06). No other
ifferences were identified between the 2 groups.
espiratory Complications
he overall rate of respiratory complications was 12.8%
n  26). Postoperative mortality in this group was 30.8%
8/26).
Acute respiratory failure requiring reintubation or non-
nvasive ventilation occurred in 10 patients (4.9%), and
hronic respiratory failure requiring oxygen administration
fter discharge occurred in 6 patients (3%). Other respira-
ory complications were pneumonia (4 cases), ARDS
3 cases), pulmonary edema (2 cases), pulmonary embolism
1 case), and atelectasis requiring bronchoscopy (1 case).
No chemo (n  103) Chemo (n  99) P value
80 79 .71
63.5 8.8 60.5 9.1 .08
27 31 .42
78.9 19.1 80.9 18.7 .43
70.7 18.3 66.4 14.8 .18
91.6 19.1 83.4 19.2 .006
40 (2) 53 (2) .03
44 52 .16
26 37 .06
149.1 38.9 138.9 38.1 .83
Dlco, diffusion capacity for carbon monoxide; Dlco/VA, diffusion capacity
ABLE 2. Mortality and morbidity by preoperative chemo-
herapy
Overall
(n  202)
Chemo
(n  99)
No chemo
(n  103) P value
ortality 4% (8) 3% (3) 4.9% (5) .05
orbidity 44% (88) 50.5% (50) 36.9% (38) .05
espiratory 13% (26) 19.1% (19) 6.8% (7) .008
ardiac 17.5% (35) 18.1% (18) 17% (17) .05
istula 5.5% (11) 5% (5) 5.9% (6) .052)
ond;emorrhage 11.5% (23) 15.1% (15) 7.9% (8) .06
and Cardiovascular Surgery ● Volume 132, Number 3 521
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5
G
TSespiratory complications were more frequent in group
than in group A (19 cases, 19.2%, vs 7 cases, 6.8%,
 .008).
redictors of Pulmonary Complications
nivariate logistic regression showed that pulmonary com-
lications were more frequent (1) in patients over the age of
0 years as compared with those aged 70 or less (25.7% vs
0.2, P  .02), (2) in those with a lower Dlco/VA (18.3%
s 5.95%, P  .06), and (3) in patients who received
reoperative chemotherapy (19.2% vs 6.8%, P  .008).
espiratory complications after right pneumonectomy were
ore frequent (15.6%) than after left pneumonectomy
10.3%), but the difference was not significant (P  .2).
atients with previous cardiac problems had a higher rate of
espiratory complications (18.9%) than did patients with no
revious cardiac events (10.4%), but the difference was not
ignificant (P  .10).
Logistic regression confirmed the role of age (P .0017,
R  6.3), preoperative chemotherapy (P  .0146, OR 
.4), and Dlco/VA% (P .0515, OR 0.33) as risk factors
ausing respiratory complications (Table 3). No risk factor
as identified by logistic regression for nonrespiratory
omplications.
iscussion
ome data exist in the scientific literature on the theoretical
ncreased risk of respiratory complications after induction
hemotherapy.5 This problem becomes crucial in patients
ho undergo pneumonectomy in which any event impairing
ulmonary function could be fatal.10
The first result from our analysis was that, after pneu-
onectomy, respiratory complications are 3 times more
requent in patients who received induction chemotherapy
han in those who did not. The supposed mechanism is a
emporary decrease in the diffusion capacity of the alveo-
ocapillary membrane, usually in the order of 15% but
ometimes as high as 40% to 50%.11 This impairment
robably amplifies the damage to the membrane caused by
nflammatory or infective agents facilitating intra-alveolar
ABLE 3. Logistic regression considering preoperative
hemotherapy, age (>70 vs < 70 years), and Dlco/VA%
> vs <88.5%, representing the median of the population)
onfirmed the role of these three factors
arameter Estimate SE 2 Point estimate CL
ntercept 2.95 0.613 0.001
reop chemo 1.48 0.608 0.014 4.419 1.34-14.5
ge 1.84 0.589 0.001 6.354 2-20.1
lco/VA% 1.10 0.568 0.051 0.331 0.1-1.007
E, Standard error; CL, confidence limits; Dlco/VA, diffusion capacity for
arbon monoxide adjusted for alveolar volume.xudates. f
22 The Journal of Thoracic and Cardiovascular Surgery ● SepteThe best functional parameter to assess membrane im-
airement is Dlco, which has been demonstrated to be a
seful independent parameter in preoperative functional
valuation of patients undergoing lung resection.12,13 Inas-
uch as Dlco is strictly linked to lung volumes, which are
odified to a variable extent in the majority of patients after
hemotherapy,14 Dlco/VA is probably a more reliable indi-
ator of membrane alteration after chemotherapy. Direct
ata on Dlco/VA loss after chemotherapy were unfortu-
ately not available in our study, because only patients who
nderwent mediastinoscopy at our institution before induc-
ion treatment had Dlco assessment both before and after
hemotherapy. However, patients who received preopera-
ive chemotherapy had a lower Dlco/VA than did those who
id not receive induction treatment, and Dlco/VA was con-
rmed as a risk factor for respiratory complications. The
ractical consequence is that it is worthwhile to study dif-
usion capacity (including Dlco/VA) both before and after
hemotherapy to identify patients with a marked impair-
ent, who could represent a high-risk group for postoper-
tive respiratory complications.
Apart from preoperative chemotherapy and Dlco/VA,
dvanced age was confirmed as an independent predictor of
espiratory complication. In fact, it has long been estab-
ished that patients older than 70 years have a higher post-
perative mortality rate than do younger patients.15-17 These
ata were confirmed by our series, in which patients over 70
ears of age represented 17% of the population and had a
ostoperative mortality of 11.4% (4/35).
Surprisingly, the increased risk for respiratory complica-
ions did not affect overall postoperative mortality, even
onsidering 90-day deaths. The reason is probably due to
he fact that chronic respiratory failure was inserted as a
ostoperative respiratory complication, whose impact on
ife expectancy should be evaluated after a longer period
han the first 3 months after surgery.
Right pneumonectomy, even after induction chemother-
py, did not show a catastrophic impact on morbidity in our
eries (overall mortality 6.2%). This was in contrast to the
eries described by Martin and associates,10 who reported a
5% mortality in patients undergoing right pneumonectomy
fter induction treatment, raising questions about the use-
ulness of such a procedure in patients with N2 disease. This
ifference is probably due to several factors: we did not
nclude extended resections, which are most often right-
ided procedures having a higher mortality; moreover, we
xcluded preoperative radiotherapy, whereas in Martin’s
eries 18% of patients received induction chemoradiother-
py. Both considerations could explain why the postpneu-
onectomy ARDS rate from the same institution remains
igh.18
During the considered period, the rate of rethoracotomyor hemostasis was high (11%). Our policy of reoperation in
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G
TSases of radiologic evidence of intrathoracic clotting and
ild progressive anemization, even in the absence of he-
odynamic instability, explains the 7% reoperation rate in
atients not receiving preoperative chemotherapy. In pa-
ients undergoing chemotherapy, the incidence of rethora-
otomy was twice that rate. The reason remains unclear,
onsidering that coagulation status was checked in all cases
he day before surgery and that surgery was postponed until
t was normal.
The supposed mechanism, postulated from liver surgery,
s a transient reduction in hepatic function caused by che-
otherapy. This effect, associated with higher blood loss
esulting from extensive mediastinal nodal dissection19 and
he azygos vein section that we routinely perform on the
ight side after chemotherapy (with a possible consequent
ncreased venous pressure on chest wall vessels), may jus-
ify the increased risk of bleeding in chemotherapy patients.
As expected, the stage distribution between groups was
ot homogeneous, because preoperative chemotherapy was
dministered to patients having a more advanced disease.
ertainly, from a speculative point of view, we can only
onfirm that these two factors (chemotherapy and stage) are
inked to a higher risk of respiratory complications, but the
eight of both factors was not evaluated. We did not
ttempt to adjust data by stage for several reasons. First, a
etrimental effect on respiratory function has been demon-
trated for chemotherapy but not for stage alone. Moreover,
tage did not affect the type of operation that patients received,
ince in all cases a standard pneumonectomy was performed.
inally, even admitting a hypothetical peculiar effect of
tage per se, this would not change our evidence-based20,21
olicy of offering induction chemotherapy to patients with
dvanced-stage lung cancer.
In conclusion, results from our series have demonstrated
hat standard pneumonectomy is a safe procedure with a
ortality rate lower than 5%, which increases in patients
ver the age of 70 years. In case of induction chemotherapy,
ortality remains under 5% but the risk of respiratory
omplications is significantly increased. In candidates for
neumonectomy after induction treatment, a complete re-
piratory assessment, mainly focused on lung diffusion,
hould be performed before and after chemotherapy to
redict postoperative risk.
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